MarketCapExport financials
Arcutis Biotherapeutics (ARQT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Arcutis Biotherapeutics Financial Ratios 2025-2011 | ARQT
Brief overview of Arcutis Biotherapeutics's financial ratios
Current figures are compared with the company's own five-year history for 2021–2025.
The valuation comparison uses P/S 9.15x (median 10.84x), P/B 18.16x (median 8.43x). Valuation is 50% above five-year reference levels. The premium requires support from earnings and returns.
The latest available business-quality ratios are ROE -8.5%, ROA -3.7%, ROCE -6.5%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
Current PEG of 6.77x points to a premium over forecast earnings momentum.
Valuation takeaway
Arcutis Biotherapeutics combines weak profitability with valuation above its historical norm, leaving limited cushion.
Annual Financial Ratios Arcutis Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-213.2 | -10.6 | -2.9 | -2.8 | -5.0 | -7.4 | - | - | - | - | - | - | - | - | - |
P/S |
9.2 | 7.6 | 12.5 | 239.2 | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-0.1 | -1.2 | -3.8 | -5.7 | -4.2 | -3.8 | -22.8 | -15.5 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
3.64 B | 1.61 B | 911 M | 1.07 B | 1.04 B | 964 M | 109 M | 35.7 M | 8.81 M | - | - | - | - | - | - |
EBITDA per Share |
-0.09 | -1.06 | -3.47 | -5.47 | -4.17 | -3.83 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-316.0 | -12.6 | -3.8 | -3.5 | -4.9 | -6.5 | - | - | - | - | - | - | - | - | - |
PEG |
6.77 | - | - | - | - | 0.03 | - | - | - | - | - | - | - | - | - |
P/B |
18.2 | 9.4 | 8.4 | 4.2 | 3.4 | 3.7 | - | - | - | - | - | - | - | - | - |
P/CF |
-611.9 | -13.2 | -3.0 | -3.4 | -5.9 | -8.9 | - | - | - | - | - | - | - | - | - |
ROE % |
-8.52 | -88.89 | -295.65 | -148.61 | -69.32 | -50.14 | - | - | - | - | - | - | - | - | - |
ROA % |
-3.73 | -40.14 | -76.79 | -69.32 | -50.56 | -45.49 | - | - | - | - | - | - | - | - | - |
ROCE % |
-6.45 | -81.50 | -271.92 | -143.92 | -69.38 | -50.49 | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.8 | 1.8 | 1.4 | 1.9 | 3.7 | 10.8 | - | - | - | - | - | - | - | - | - |
DSO |
106.4 | 91.8 | 104.9 | 418.8 | - | - | - | - | - | - | - | - | - | - | - |
DIO |
184.8 | 263.9 | 755.6 | 1818.7 | - | - | - | - | - | - | - | - | - | - | - |
DPO |
133.0 | 250.1 | 761.9 | 3916.2 | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
291.2 | 355.7 | 860.5 | 2237.5 | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
158.2 | 105.6 | 98.7 | -1678.8 | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Arcutis Biotherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.11 | -0.09 | 0.06 | -0.13 | -0.2 | - | -0.33 | -0.42 | -0.32 | - | -0.73 | -1.16 | -1.31 | - | -1.89 | -1.31 | -1.27 | - | -1.14 | -0.84 | -0.76 | -0.79 | -1.01 | -0.94 | -1.15 | -6.13 | -7.56 | -4.69 | -4.08 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.13 | -65.9 | 0.1 | - | -0.19 | - | - | -0.4 | -0.28 | - | -0.59 | -1.08 | -1.24 | - | -1.83 | -1.28 | -1.24 | - | -1.14 | -0.84 | -0.76 | - | -1.01 | -0.95 | -1.18 | - | -7.62 | -4.82 | -4.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-5.89 | -30.27 | -50.83 | -83.59 | -87.88 | -70.32 | -166.14 | -227.80 | -257.05 | -241.32 | -281.10 | -219.78 | -156.95 | -99.62 | -115.32 | -85.68 | -59.17 | -33.82 | -46.41 | -44.83 | -47.78 | -50.14 | -18.23 | 18.16 | 43.99 | 64.58 | 22.27 | 12.75 | 10.24 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-1.89 | -12.25 | -19.29 | -33.05 | -35.94 | -28.66 | -43.94 | -56.58 | -65.92 | -58.53 | -79.69 | -82.08 | -74.66 | -53.55 | -63.26 | -42.09 | -49.74 | -32.07 | -43.49 | -41.57 | -43.74 | -45.49 | -45.82 | -46.54 | -42.41 | -39.24 | -13.53 | -7.75 | -6.22 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-2.46 | -27.11 | -47.25 | -79.51 | -83.05 | -65.86 | -144.85 | -202.84 | -230.56 | -216.50 | -255.19 | -209.88 | -151.63 | -97.05 | -112.78 | -84.25 | -58.56 | -33.88 | -48.03 | -45.47 | -45.91 | -37.91 | -15.38 | 11.90 | 35.76 | 46.35 | 22.53 | 13.13 | 10.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.8 | 1.7 | 1.7 | 1.6 | 1.7 | 1.8 | 1.6 | 1.7 | 1.9 | 1.4 | 1.2 | 1.3 | 1.6 | 1.9 | 2.1 | - | 3.3 | 3.7 | 16.1 | 23.5 | 23.1 | 10.8 | 10.8 | 10.8 | 10.8 | 19.3 | 19.3 | 19.3 | 19.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
105.2 | 112.3 | 102.0 | 107.5 | 109.8 | - | 105.5 | 119.1 | 58.0 | - | 43.9 | 263.5 | 348.2 | - | 153.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
318.1 | 278.9 | 203.5 | 200.6 | 160.9 | - | 231.3 | 357.3 | 369.7 | - | 941.3 | 1118.6 | 936.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
103.8 | 112.3 | 109.7 | 241.2 | 200.2 | - | 226.1 | 275.4 | 349.8 | - | 1170.9 | 1742.8 | 1241.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 308.1 | 270.7 | - | 336.8 | 476.4 | 427.6 | - | 985.2 | 1382.1 | 1284.3 | - | 153.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 66.9 | 70.5 | - | 110.7 | 201.0 | 77.8 | - | -185.8 | -360.6 | 42.5 | - | 153.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Arcutis Biotherapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Israel
Japan
Canada
Schweiz
China
Germany
Britain
